Emcure Q3FY26 results show 20% YoY revenue growth and 48% rise in PAT, driven by strong domestic performance and robust international expansion.
Read MoreSatish Mehta
Emcure Pharmaceuticals Q2FY26 Results: INR 2,270 Cr Revenue and 25 Per Cent Profit Growth
Emcure Pharmaceuticals Q2FY26 results report ₹2,270 crore revenue, 25% PAT growth, and strong domestic and international market performance.
Read More
Novo Nordisk India Partners with Emcure Pharma to Launch Poviztra for Weight Management
Novo Nordisk India partnership with Emcure Pharma launches Poviztra, expanding access to semaglutide-based weight management treatment in India.
Read More
Emcure Pharmaceuticals Q1 FY26: Revenue at INR 2101 Cr, PAT Rises 41 Per Cent
Emcure Pharmaceuticals Q1 FY26 performance was bolstered by healthy momentum across both domestic and international markets.
Read More
Emcure Secures Exclusive Distribution Rights for Sanofi India’s Oral Anti-diabetic Drugs
Emcure will exclusively promote and distribute Sanofi’s oral anti-diabetic drugs brands, including the widely prescribed Amaryl and Cetapin, throughout India.
Read More
Emcure Pharmaceuticals Posts 63 Per Cent PAT Growth in Q4FY25
Emcure Pharmaceuticals continues to expand its presence in 70+ countries, including major global markets like Europe and Canada.
Read More